|
KMID : 0378019900330020100
|
|
New Medical Journal
1990 Volume.33 No. 2 p.100 ~ p.108
|
|
|
A Comparative Study for the Effect of Diacerhein(Artrodar^(®)) with Piroxicam to the Degenerative Arthritic Disease
|
|
|
|
|
Abstract
|
|
|
Degenerative arthritic diseases at present constitute a serious social problem. No drugs are currently available which are capable of correcting the impaired metabolism and function of particular cartilage and it is thus unfortunately impossible to carry out etiological therapy of arthrosis.
Treatment of degenerative arthrosis is still based mainly on antiinflammatory analgesic drugs, such as corticosteroid, and
nonsteroidal antiinflammatory drugs(NSAIDs), aspirin, phenylbutazone, indomethacin, ibuprofen, naproxen, piroxicam etc. But these are not tclerable because of adverse gastric action.
Diacerhein(Artrodar®) is a molecule possessing new mechanisms of
action and is capable of attacking the symptoms and possibly the pathogenesis of the arthritic process, this is particularly interested in the unusual characteristics that have emerged from thorough experimental and clinical studies.
To obtain the clinical results of the Diacerhein, we choose 40 out-patients (13 males, 27 females, average age 54 years) who suffered from
knee joint arthralgia. And we divided into two groups of 20 each, a experimental model of double-blind controlled study was mace, one treated with piroxicam and one with Diacerhein.
The first group was given treatment with two 10mg piroxicam
capsules a day and the second was treated with two 50mg Diacerhein capsules a day.
The period of treatment was 6 weeks and following 2 weeks we treated the patients with placebo which is same external appearance as testing drugs.
We considered the effects of the preparations on the pain symptoms and articular efficiency, clinical tolerance, side effects, as well as any blood biohumoral variations, recorded at the end of treatment in comparison with the starting conditions. With particular reference to the arthrosis symptoms recorded by the physicians at 3rd, 6th, and 8th weeks.
We feel that the analgesic action of the test compound is demonstrated. From the clinical point of view it appeared to be slightly better than that of piroxicam right from the first observations. However the statistical analysis between two groups was not found to be significant.
A favorable change is observed at 8th weeks, the Diacerhein group is on the same conditions as 6th weeks, but the piroxicam group is more aggravated of symptoms compared w: th 6th weeks.
We may therefore deduce that the test drug showed excellent clinical tolerance and reliable effectiveness in all parameters evaluated in the field of degenerative arthritis, acting fairly selectively on pain, and hence showing good analgesic properties. This enables us to assert that Diacerhein is a reliable effective drug in the field of painful and inflammatory manifestations characterising the disease of degenerative arthrosis.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|